clinical trial · NCT05887609
An Evaluation of Maintenance Therapy Combination Mirvetuximab Soravtansine and Olaparib
University of Colorado, Denver·phase2·recruiting·n = 53
Ovary CancerPeritoneal CancerFallopian Tube CancerMirvetuximab Soravtansine-gynxOlaparib
brief summary
The Principal Investigator hypothesizes the combination of MIRV and Olaparib is an effective, and tolerable, maintenance therapy strategy in platinum sensitive recurrent ovarian cancer.
started
Oct 3, 2023
primary completion
Jan 31, 2029
completion
Jan 31, 2031
last updated
Apr 13, 2026
official title
A Phase II Evaluation of Maintenance Therapy Combination Mirvetuximab Soravtansine-gynx and Olaparib in Recurrent Platinum Sensitive Ovarian, Peritoneal, and Fallopian Tube Cancer
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol